2I3 Stock Chart & Stats
€5.15
-€0.10(-1.90%)
At close: 4:00 PM EDT
€5.15
-€0.10(-1.90%)
Day’s Range― - ―
52-Week Range€4.46 - €6.75
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€64.57M
Enterprise Value€82.62
Total Cash (Recent Filing)€4.87M
Total Debt (Recent Filing)€4.60M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Sep 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding13,893,569
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.93
Price to Sales (P/S)1.39
P/FCF Ratio-16.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.09
Revenue Forecast (FY)€57.38M
Bulls Say, Bears Say
Bulls Say
Core Services Revenue GrowthSustained, double-digit growth in core study revenue reflects durable demand for Champions' fee-for-service oncology models. Strong backlog conversion and repeat customer study execution support predictable medium-term service revenue and improve prospects for steady cash generation as scale persists.
Consistent Adjusted EBITDA MomentumRepeated positive adjusted EBITDA shows underlying operational discipline and fixed-cost leverage in the services business. This persistent profitability metric supports reinvestment in growth initiatives, reduces near-term funding pressure, and increases the likelihood of sustainable operating cash flow over the next several quarters.
Strategic Diversification: Data & CorelliaEarly commercial traction in a nascent data platform plus progress at Corellia create paths to higher-margin, recurring and licensing revenue beyond services. If scaled, these structural initiatives can diversify revenue mix and lift long-term growth potential and margin expansion over a multi-quarter horizon.
Bears Say
Volatile Cash GenerationA sharp flip from positive to negative cash flow demonstrates inconsistent conversion of revenue into cash. This volatility increases the probability of external financing needs, complicates multi‑period planning, and makes the company more vulnerable to timing swings in study completions and client payments.
Thin Equity Cushion And Leverage RiskA small equity base and history of negative shareholder equity limit the balance-sheet buffer against operational setbacks. Modest absolute debt with prior elevated debt-to-equity ratios raises refinancing and liquidity risk and constrains the company's ability to absorb adverse shocks without dilutive or costly capital raises.
Margin Pressure From Outsourced Costs & Higher OpExMaterial gross margin compression driven by outsourced radiolabeling and rising operating expenses weakens core profitability. Unless the company internalizes key workflows or reduces outsources and overhead, structural margin pressure could persist and limit free cash flow improvement despite service revenue growth.
Champions Oncology News
2I3 FAQ
What was Champions Oncology Inc’s price range in the past 12 months?
Champions Oncology Inc lowest stock price was €4.46 and its highest was €6.75 in the past 12 months.
What is Champions Oncology Inc’s market cap?
Champions Oncology Inc’s market cap is €64.57M.
When is Champions Oncology Inc’s upcoming earnings report date?
Champions Oncology Inc’s upcoming earnings report date is Sep 16, 2026 which is in 43 days.
How were Champions Oncology Inc’s earnings last quarter?
Champions Oncology Inc released its earnings results on Jul 27, 2026. The company reported €0.009 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Champions Oncology Inc overvalued?
According to Wall Street analysts Champions Oncology Inc’s price is currently Overvalued.
Does Champions Oncology Inc pay dividends?
Champions Oncology Inc does not currently pay dividends.
What is Champions Oncology Inc’s EPS estimate?
Champions Oncology Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Champions Oncology Inc have?
Champions Oncology Inc has 13,893,569 shares outstanding.
What happened to Champions Oncology Inc’s price movement after its last earnings report?
Champions Oncology Inc reported an EPS of €0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.943%.
Which hedge fund is a major shareholder of Champions Oncology Inc?
Currently, no hedge funds are holding shares in DE:2I3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Champions Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:2I3 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.56%
Trailing 12-Months
Company Description
Champions Oncology Inc
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
2I3 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid operational execution — record services revenue, ~32% growth in core study revenue, and a third consecutive positive adjusted EBITDA — alongside deliberate investments in data and a therapeutic subsidiary (Corellia). However, near-term challenges include a modest overall revenue decline (~3%) driven by absence of prior-year data license revenue, compression of gross margin (61% to 47%) driven in part by outsourced radiolabeling costs, and elevated operating expenses (~+36%). Data revenue remains early and variable, and Corellia funding timing is uncertain. On balance, the positive operational momentum and pathway to monetize data and Corellia slightly outweigh the near-term margin and timing headwinds.View all DE:2I3 earnings summariesTechnical Analysis
Oncolytics Biotech
―
―
Cardiff Oncology
―
MaxCyte
―
Black Diamond Therapeutics
―
Lantern Pharma
―